Triveni Bio Launches With $92 Million Series A Financing To Advance Genetics-Informed Precision Medicines For The Treatment Of Immunological And Inflammatory (I&I) Disorders
Triveni Bio Launches With $92 Million Series A Financing To Advance Genetics-Informed Precision Medicines For The Treatment Of Immunological And Inflammatory (I&I) Disorders
10/26/23, 10:03 AM
Location
walthamMoney raised
$92 million
Industry
biotechnology
health care
Round Type
series a
Investors
Alexandria Venture Investments, Polaris Partners, Invus, Viking Global Investors, Orbi Med, Cormorant Asset Management, Atlas Venture
Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.
Company Info
Location
waltham, massachusetts, united states
Additional Info
Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact.